Skip to main content

#153224

Anti-CD21 [BU79]

Cat. #153224

Anti-CD21 [BU79]

Cat. #: 153224

Unit size: 100 ug

Availability: 3-4 weeks

Target: CD21

Class: Monoclonal

Application: IHC

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Margaret Goodall

Institute: University of Birmingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CD21 [BU79]
  • Alternate name: Complement receptor type 2; CR2; complement C3d receptor, C3DR, Epstein-Barr virus receptor
  • Research fields: Immunology
  • Clone: BU80
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC
  • Description: Cluster of differentiation 21 (CD21) is a protein encoded by the CR2 gene in humans. It is involved in the complement system and binds to iC3b (an inactive derivative of C3b). B cells are known to have CR2 receptors on their surfaces allowing the complement system to act in B-cell maturation and activation. Genetic variations are associated with susceptibility to systemic lupus erythematosus type 9 (SLEB9) which is a chronic autoimmune disease with an inflammatory, and often febrile multisystemic disorder of connective tissue characterized principally by involvement of the skin, joints, kidneys, and serosal membranes.
  • Immunogen: Daudi cell line (B lymphoblast)
  • Isotype: IgG1

Target Details

  • Target: CD21
  • Target background: Cluster of differentiation 21 (CD21) is a protein encoded by the CR2 gene in humans. It is involved in the complement system and binds to iC3b (an inactive derivative of C3b). B cells are known to have CR2 receptors on their surfaces allowing the complement system to act in B-cell maturation and activation. Genetic variations are associated with susceptibility to systemic lupus erythematosus type 9 (SLEB9) which is a chronic autoimmune disease with an inflammatory, and often febrile multisystemic disorder of connective tissue characterized principally by involvement of the skin, joints, kidneys, and serosal membranes.

Applications

  • Application: IHC

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

References

  • Leucocyte Typing VI, (1998): edited by T. Kishimoto, Garland Publishing, New York.
  • Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663.
  • Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663.
  • Buescher et al. 1991. Public Health Rep. 106(3):333-8. PMID: 1905057.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.